XML 26 R16.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Shareholders' Equity and Share-based Compensation | 3 Months Ended
--- | ---
Dec. 31, 2022
Share-Based Payment Arrangement, Noncash Expense [Abstract] |
Shareholders' Equity and Share-based Compensation | Shareholders' Equity and Share-based Compensation Share Repurchase In September 2017, the Board of Directors approved a repurchase program (the “Repurchase Program”) that allowed the Company to repurchase its common shares from the open market pursuant to a pre-established Rule 10b5-1 trading plan or through privately negotiated transactions up to an aggregate of $30.0 million. The amount and timing of any repurchases under the Repurchase Program depend on a number of factors, including but not limited to, the trading price, volume and availability of the Company’s common shares. Shares repurchased under this program are accounted for as treasury shares and the total cost of shares repurchased is recorded as a reduction of shareholders' equity. From time to time, treasury shares may be reissued as part of the Company’s share-based compensation programs. Gains on re-issuance of treasury stock are credited to additional paid-in capital; losses are charged to additional paid-in capital to offset the net gains, if any, from previous sales or re-issuance of treasury stock. Any remaining balance of the losses is charged to retained earnings. As of December 31, 2023, the Company had repurchased an aggregate of 7,332,780 shares for a total cost of $81.1 million, at an average price of $11.01 per share, excluding fees and related expenses. No repurchased shares have been retired. Of the 7,332,780 repurchased shares, 178,349 shares with a weighted average repurchase price of $9.94 per share, were reissued at an average price of $4.69 per share pursuant to option exercises and vested restricted share units (“RSU”). As of December 31, 2023, no remaining amount was available under the share repurchase program, which has been terminated. Time-based Restric ted Stock Units (“TRSU”) The following table summarizes the Company's TRSU activities for the six months ended December 31, 2023:
| Number of Restricted Stock Units |  | Weighted Average Grant Date Fair Value Per Share |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value
Nonvested at June 30, 2023 | 1,385,065 |  |  | $ | 32.48 |  |  | 1.73 |  | $ | 45,430,132 |
Granted | 121,951 |  |  | $ | 28.46 |  |  |  |  |
Vested | (82,517) |  |  | $ | 30.26 |  |  |  |  |
Forfeited | (24,601) |  |  | $ | 34.88 |  |  |  |  |
Nonvested at December 31, 2023 | 1,399,898 |  |  | $ | 32.22 |  |  | 1.34 |  | $ | 36,481,342 |
Market-based Restricted Stock Units (“MSU”) In December 2021, the Company granted 1.0 million market-based restricted stock units ("MSUs") to certain personnel. The number of shares to be earned at the end of performance period was determined based on the Company’s achievement of specified stock prices and revenue thresholds during the performance period from January 1, 2022 to December 31, 2024 as well as the recipients remaining in continuous service with the Company through such period. The MSU vests in four equal annual installments after the end of performance period. The Company estimated the grant date fair values of its MSUs using a Monte-Carlo simulation model. On September 19, 2023, the Compensation Committee of the Board approved a modification of the terms of MSUs to extend the performance period through December 31, 2025, changed the commencement date for the four-year time-based service period January 1, 2025, and reduced the achievement of specified stock prices and revenue thresholds. The fair value of these MSUs was revalued to reflect the change using a Monte-Carlo simulation model with the following assumptions: risk-free interest rate of 4.94%, expected term of 2.28 years, expected volatility of 61.38% and dividend yield of 0%. The Company recognizes the total compensation cost of the modified MSUs beginning on the modification date over the remaining requisite service periods. The Company recorded $1.2 million of expenses for the three months ended December 31, 2023, and a negative $5.1 million of expenses for the six months ended December 31, 2023 due to a $6.4 million of reversal of the prior recognized expenses. The Company recorded $2.1 million and $4.1 million of expenses for the three and six months ended December 31, 2022, respectively. During the quarter ended September 30, 2018, the Company granted 1.3 million MSUs to certain personnel. The number of shares to be earned at the end of performance period is determined based on the Company’s achievement of specified stock prices and revenue thresholds during the performance period from January 1, 2019 to December 31, 2021 as well as the recipients remaining in continuous service with the Company through such period. The MSUs vest in four equal annual installments after the end of the performance period. The Company estimated the grant date fair values of its MSUs using a Monte-Carlo simulation model. On August 31, 2020, the Compensation Committee of the Board approved a modification of the terms of MSU to (i) extend the performance period through December 31, 2022 and (ii) change the commencement date for the four-year time-based service period to January 1, 2023. The fair value of these MSUs was recalculated to reflect the change as of August 31, 2020 and the unrecognized compensation amount was adjusted to reflect the increase in fair value. The Company recorded $0.3 million and $0.6 million of expenses for MSUs during the three and six months ended December 31, 2023, respectively, and $2.8 million and $3.3 million of expenses for MSUs during the three and six months ended December 31, 2022. The following table summarizes the Company's MSUs activities for the six months ended December 31, 2023:
| Number of Performance-based Restricted Stock Units |  | Weighted Average Grant Date Fair Value Per Share |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value
Nonvested at June 30, 2023 | 2,108,000 |  |  | $ | 25.86 |  |  | 2.96 |  | $ | 69,142,400 |
Granted | — |  |  | $ | — |  |  |  |  |
Vested | (275,000) |  |  | $ | 5.17 |  |  |  |  |
Forfeited | — |  |  | $ | — |  |  |  |  |
Nonvested at December 31, 2023 | 1,833,000 |  |  | $ | 28.96 |  |  | 3.37 |  | $ | 47,767,980 |
Performance-based Restricted Stock Units (“PRSUs”) In March each year since year 2017, the Company granted PRSUs to certain personnel. The number of shares to be earned under the PRSUs is determined based on the level of attainment of predetermined financial goals. The PRSUs vest in four equal annual installments from the first anniversary date after the grant date if certain predetermined financial goals were met. The Company recorded approximately $0.8 million and $1.2 million of e xpens e for these PRSUs during the three and six months ended December 31, 2023, respectively, and $1.1 million and $2.7 million and for the three and six months ended December 31, 2022, respectively. The following table summarizes the Company’s PRSUs activities for the six months ended December 31, 2023:
| Number of Performance-based Restricted Stock Units |  | Weighted Average Grant Date Fair Value Per Share |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value
Nonvested at June 30, 2023 | 526,714 |  |  | $ | 32.19 |  |  | 1.78 |  | $ | 17,276,219 |
Granted | — |  |  | $ | — |  |  |  |  |
Vested | — |  |  | $ | — |  |  |  |  |
Forfeited | — |  |  | $ | — |  |  |  |  |
Nonvested at December 31, 2023 | 526,714 |  |  | $ | 32.19 |  |  | 1.29 |  | $ | 13,726,167 |
Stock Options The Company did not grant any stock options during the six months ended December 31, 2023 and 2022. The following table summarizes the Company's stock option activities for the six months ended December 31, 2023:
|  |  |  |  |  |  | Weighted |  |
|  |  | Weighted |  |  |  | Average |  |
|  |  | Average |  |  |  | Remaining |  |
| Number of |  | Exercise Price |  |  |  | Contractual |  | Aggregate
| Shares |  | Per Share |  |  |  | Term (in years) |  | Intrinsic Value
Outstanding at June 30, 2023 | 319,375 |  |  | $ | 7.53 |  |  |  |  | 0.72 |  | $ | 8,071,631 |
Exercised | (157,500) |  |  | $ | 7.45 |  |  |  |  |  |  | $ | 1,732,188 |
Outstanding at December 31, 2023 | 161,875 |  |  | $ | 7.61 |  |  |  |  | 0.25 |  | $ | 2,987,294 |
Options vested and expected to vest | 161,875 |  |  | $ | 7.61 |  |  |  |  | 0.25 |  | $ | 2,987,294 |
Exercisable at December 31, 2023 | 161,875 |  |  | $ | 7.61 |  |  |  |  | 0.25 |  | $ | 2,987,294 |
Employee Share Purchase Plan (“ESPP”) The assumptions used to estimate the fair values of common shares issued under the ESPP were as follows:
| Six Months Ended December 31,
| 2023 |  |
Volatility rate | 64.0% |  |
Risk-free interest rate | 5.2% |  |
Expected term | 1.3 years |  |
Dividend yield | 0% |  |
Share-based Compensation Expense The total share-based compensation expense recognized in the Condensed Consolidated Statements of Income for the periods presented was as follows:
| Three Months Ended December 31, |  | Six Months Ended December 31,
| 2023 |  | 2022 |  | 2023 |  | 2022
| (in thousands) |  | (in thousands)
Cost of goods sold | $ | 1,504 |  |  | $ | 1,748 |  |  | $ | 1,716 |  |  | $ | 3,536 |
Research and development | 2,417 |  |  | 3,327 |  |  | 2,423 |  |  | 5,821 |
Selling, general and administrative | 4,770 |  |  | 8,016 |  |  | 5,470 |  |  | 14,330 |
| $ | 8,691 |  |  | $ | 13,091 |  |  | $ | 9,609 |  |  | $ | 23,687 |
As of December 31, 2023, total unrecognized compensation cost under the Company's equity plans was $48.7 million, which is expected to be recognized over a weighted-average period of 2.5 years.

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration